H.C. Wainwright raised the firm’s price target on Niagen Bioscience (NAGE) to $12 from $11 and keeps a Buy rating on the shares. The company’s Q2 revenue and earnings beat expectations, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NAGE:
- Niagen Bioscience’s Robust Growth and Strategic Initiatives Drive Buy Rating
- Niagen Bioscience Reports Strong Q2 Growth and Outlook
- Niagen Bioscience Reports Strong Q2 Sales Growth
- Niagen Bioscience reports Q2 EPS 4c, consensus 1c
- Niagen Bioscience: Promising Clinical Results and Strategic IP Acquisitions Drive Buy Rating